We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cymabay Therapeutics Inc | NASDAQ:CBAY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 32.48 | 34.10 | 30.85 | 0 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
CymaBay Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
23257D103
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 23257D103 | 13G |
1. | NAMES OF REPORTING PERSONS
TCG Crossover GP I, LLC | |||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒
| |||||
3. | SEC USE ONLY
| |||||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5. | SOLE VOTING POWER
0 | ||
6. | SHARED VOTING POWER
0 | |||
7. | SOLE DISPOSITIVE POWER
0 | |||
8. | SHARED DISPOSITIVE POWER
0 |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | |||||
10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
☐ | |||||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | |||||
12. | TYPE OF REPORTING PERSON (see instructions)
OO |
CUSIP No. 23257D103 | 13G |
1. | NAMES OF REPORTING PERSONS
TCG Crossover Fund I, L.P. | |||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒
| |||||
3. | SEC USE ONLY
| |||||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5. | SOLE VOTING POWER
0 | ||
6. | SHARED VOTING POWER
0 | |||
7. | SOLE DISPOSITIVE POWER
0 | |||
8. | SHARED DISPOSITIVE POWER
0 |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | |||||
10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
☐ | |||||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | |||||
12. | TYPE OF REPORTING PERSON (see instructions)
PN |
CUSIP No. 23257D103 | 13G |
1. | NAMES OF REPORTING PERSONS
Chen Yu | |||||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒
| |||||
3. | SEC USE ONLY
| |||||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5. | SOLE VOTING POWER
0 | ||
6. | SHARED VOTING POWER
0 | |||
7. | SOLE DISPOSITIVE POWER
0 | |||
8. | SHARED DISPOSITIVE POWER
0 |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | |||||
10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
☐ | |||||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0% | |||||
12. | TYPE OF REPORTING PERSON (see instructions)
IN |
CUSIP No. 23257D103 | 13G |
Explanatory Note
This Amendment No. 2 (Amendment No. 2) amends and supplements the Schedule 13G initially filed with the Securities and Exchange Commission (the Commission) on November 29, 2021, as amended by Amendment No. 1 filed with the Commission on February 14, 2023 (collectively, the Original Schedule 13G) and is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I and together with TCG Crossover I, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is filed as Exhibit 1 to the Original Schedule 13G. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 2 have the meanings ascribed to them in the Original Schedule 13G.
Item 4. | Ownership. |
(a) Amount beneficially owned:
See Row 9 of the cover page for each Reporting Person.*
(b) Percent of class:
See Row 11 of the cover page for each Reporting Person.*
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
See Row 5 of the cover page for each Reporting Person.*
(ii) Shared power to vote or to direct the vote
See Row 6 of the cover page for each Reporting Person.*
(iii) Sole power to dispose or to direct the disposition of
See Row 7 of the cover page for each Reporting Person.*
(iv) Shared power to dispose or to direct the disposition of
See Row 8 of the cover page for each Reporting Person.*
* | Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. |
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5% of the class of securities, check the following: ☒
Material to be Filed as Exhibits.
Exhibit 24 Power of Attorney (Craig Skaling).
CUSIP No. 23257D103 | 13G |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2024
TCG Crossover Fund I, L.P. | ||
By: | TCG Crossover GP I, LLC | |
Its: | General Partner | |
By: | /s/ Craig Skaling | |
Authorized Signatory | ||
TCG Crossover GP I, LLC | ||
By: | /s/ Craig Skaling | |
Authorized Signatory |
/s/ Craig Skaling as attorney-in-fact for Chen Yu |
Chen Yu |
Exhibit 24
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints Craig Skaling as the undersigneds true and lawful attorney-in-fact (the Attorney-in-Fact) to:
1. | execute for and on behalf of the undersigned (the Reporting Person) a Form ID Application and/or Update Passphrase Confirmation, if required, and submit the same to the United States Securities and Exchange Commission (the Commission); |
2. | execute for and on behalf of the Reporting Person any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 13-F, Form 3, Form 4 and Form 5) that such Reporting Person may be required to file with the Commission pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (collectively, the Reports) with respect to the Reporting Persons (a) status as an officer or director of, or (b) ownership of, or transactions in, securities of, any entity whose securities are beneficially owned (directly or indirectly) by such Reporting Person (each, a Company); |
3. | do and perform any and all acts for and on behalf of the Reporting Person which may be necessary or desirable to complete and execute any such Reports and timely file such forms and schedules with the Commission and any stock exchange or similar authority; and |
4. | take any other action of any type whatsoever in connection with the foregoing which, in the opinion of the Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by the Attorney-in-Fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as the Attorney-in-Fact may approve in the Attorney-in-Facts discretion. |
The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that the Attorney-in-Fact, or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5, Form 13F or Schedules 13G/D with respect to the undersigneds holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. The Reporting Person acknowledges that the Attorney-in-Fact, in serving in such capacity at the request of the undersigned, is not hereby assuming any of the undersigneds responsibilities to comply with Section 13 or Section 16 of the Securities Exchange Act of 1934 and state or federal securities laws. This Power of Attorney may be filed with the Commission as a confirming statement of the authority granted herein.
[SIGNATURES ON THE FOLLOWING PAGE.]
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this February 8, 2024.
TCG Crossover Fund I, L.P. | ||
By: | TCG Crossover GP I, LLC | |
Its: | General Partner | |
By: | /s/ Chen Yu | |
Chen Yu | ||
Managing Member | ||
TCG Crossover GP I, LLC | ||
By: | /s/ Chen Yu | |
Chen Yu | ||
Managing Member | ||
TCG Crossover Fund II, L.P. | ||
By: | TCG Crossover GP II, LLC | |
Its: | General Partner | |
By: | /s/ Chen Yu | |
Chen Yu | ||
Managing Member | ||
TCG Crossover GP II, LLC | ||
By: | /s/ Chen Yu | |
Chen Yu | ||
Managing Member |
/s/ Chen Yu | ||
Chen Yu |
1 Year Cymabay Therapeutics Chart |
1 Month Cymabay Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions